10-Q: America Great Health Reports Q1 2026 Results Amidst Going Concern

America Great Health's Q1 2026 filing reveals a significant decrease in sales and continued operational losses, raising substantial doubt about its ability to continue as a going concern.

Summary

• America Great Health reported a net loss of $166,216 for the three months ended March 31, 2026, compared to a loss of $158,377 for the same period in 2025.
• For the nine months ended March 31, 2026, the company reported a net income of $861,105, a significant improvement from a net loss of $499,046 in the prior year period.
• This net income for the nine-month period was largely driven by a non-recurring gain of $1,395,000 from the extinguishment of debt.
• Sales for the three months ended March 31, 2026, decreased to $26,143 from $56,148 in the prior year, attributed to the absence of major U.S. wholesale accounts.
• Sales for the nine months ended March 31, 2026, were $258,802, down from $287,213 in the prior year, also due to a temporary gap in U.S. bulk wholesale orders.
• The company has a shareholders' deficit of $4,880,635 as of March 31, 2026, and negative working capital of $2,478,411.
• The filing explicitly states that these factors create substantial doubt about the company's ability to continue as a going concern within the next twelve months.
• Cash used in operating activities increased to $80,272 for the nine months ended March 31, 2026, from $60,297 in the prior year period.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as negative due to significant recurring losses, a substantial shareholders' deficit, and a going concern warning, despite a reported net income in the latest nine-month period driven by a one-time gain.

Positives

• Reported a net income of $861,105 for the nine months ended March 31, 2026, a substantial turnaround from a net loss of $499,046 in the comparable prior year period.
• The net income for the nine-month period was significantly boosted by a $1,395,000 non-recurring gain from the extinguishment of aged accounts payable.
• Operating expenses decreased for both the three-month ($96,308 vs $135,136) and nine-month ($447,682 vs $538,397) periods ended March 31, 2026, primarily due to reduced general and administrative expenses.
• Net cash provided by financing activities increased to $52,475 for the nine months ended March 31, 2026, from $43,314 in the prior year, partly due to a new $50,000 loan.
• The company has a cash balance of $29,346 as of March 31, 2026, which it intends to use, along with advances from its majority shareholder, to finance operations over the next twelve months.

Negatives

• Incurred a net loss of $166,216 for the three months ended March 31, 2026.
• Sales declined significantly for both the three-month period ($26,143 vs $56,148) and the nine-month period ($258,802 vs $287,213) ended March 31, 2026.
• The company has a substantial shareholders' deficit of $4,880,635 as of March 31, 2026.
• Working capital is negative at $2,478,411 as of March 31, 2026.
• The filing explicitly raises substantial doubt about the company's ability to continue as a going concern.
• Cash used in operating activities increased to $80,272 for the nine months ended March 31, 2026, from $60,297 in the prior year.
• The company's auditor previously issued a disclaimer of opinion due to insufficient evidence on expenses, opening balances, and the Purecell investment.

Risks

• The company has incurred recurring net losses, creating substantial doubt about its ability to continue as a going concern.
• The company's ability to continue as a going concern is dependent on securing additional sources of capital and the success of its plans to achieve profitable operations.
• There is no assurance that the company will be successful in raising additional capital or in achieving profitable operations.
• The company's disclosure controls and procedures are not effective, with material weaknesses identified including lack of a functioning audit committee, insufficient accounting staff and resources, lack of independent directors, and an ineffective review process.
• The company is not required to provide detailed risk factor disclosures as a smaller reporting company.

Future Outlook

The company's new majority shareholders will need to provide parts of its working capital going forward. The company intends to finance operating costs over the next twelve months with existing cash on hand and advances from sales and the current majority shareholder. The company is raising additional capital to achieve profitable operations.

Management Comments

• Management believes that the material weaknesses set forth in above did not have an effect on our financial results.
• Management believes that the lack of a functioning audit committee and the lack of a majority of outside directors on our board of directors results in ineffective oversight in the establishment and monitoring of required internal controls and procedures, which could result in a material misstatement in our financial statements in future periods.
• The company's mission is to invest in innovative technologies integrated with business development in the healthcare ecosystem.

Industry Context

StockSavvy.ai notes that the healthcare and supplements sector is highly competitive and often characterized by companies with complex R&D pipelines and regulatory hurdles. America Great Health's focus on protein and peptide drugs, diagnostics, and supplements aligns with emerging trends, but its financial performance indicates significant challenges in scaling operations and achieving profitability.

Comparison to Industry Standards

• The company's sales performance for the nine months ended March 31, 2026 ($258,802) is significantly lower than many established players in the healthcare and supplements industry, which often report revenues in the hundreds of millions or billions.
• The substantial shareholders' deficit and going concern warning are critical indicators that the company is not meeting industry standards for financial stability and operational viability.
• The reported net income for the nine-month period, driven by a one-time debt extinguishment gain, is not indicative of sustainable operational performance, which is a key benchmark in the industry.

Corporate Governance

Legal Proceedings

• The company is not a party to or otherwise involved in any legal proceedings.
• In the ordinary course of business, the company is from time to time involved in various pending or threatened legal actions, but management believes these are not expected to have a material adverse effect on financial position or results of operations.

Related Party Transactions

• The company's current majority shareholder advanced $205,478 to the company and the company repaid $203,003 to the shareholder in the nine months ended March 31, 2026.
• As of March 31, 2026, the company owed its current majority shareholder $1,254,114.

Stakeholder Impact

• Shareholders may be concerned about the company's going concern status and the significant shareholders' deficit.
• The lack of effective internal controls and disclosure procedures could lead to misstatements impacting investor confidence.
• The reliance on majority shareholder advances for working capital indicates a potential dependency that could affect future strategic decisions.

Next Steps

• The company intends to finance operating costs over the next twelve months with existing cash on hand and advances from sales and the current majority shareholder.
• The company is raising additional capital to achieve profitable operations.
• The company's new majority shareholders will need to provide parts of its working capital going forward.

Key Dates

Recommendation

The company exhibits significant financial distress, including recurring losses, a substantial shareholders' deficit, negative working capital, and explicit warnings about its ability to continue as a going concern. While a one-time gain improved the nine-month net income, the underlying operational performance remains weak, with declining sales and increased cash burn from operations. The identified material weaknesses in internal controls further exacerbate the risk profile, making it difficult to rely on the reported financial information. These factors collectively suggest a high risk for investors.

Keywords

healthcare, supplements, protein, peptide, cell therapy, regenerational medicine, diagnostic devices, AI